Jon Napitupulu

Madrigal Pharmaceuticals posted third-quarter 2025 net sales of $287.3 million for Rezdiffra, bringing the total number of treated patients...

AC Immune has completed a strategic review, narrowed its investment focus to three Phase 2 active immunotherapies and a...

Rhythm Pharmaceuticals reported third-quarter 2025 net product revenue of $51.3 million and, more importantly, secured FDA priority review for...

Werewolf Therapeutics outlined a pivotal fourth quarter ahead, anchored by a Fast Track designation for WTX-124 in post-immunotherapy cutaneous...

Taysha Gene Therapies has secured FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome, finalized alignment with the agency...

Kura Oncology has advanced its menin inhibitor, ziftomenib, on two fronts at once: the FDA is reviewing the new...

Recludix Pharma will present at two investor conferences in November, with webcasts available for 30 days after each session....

Pyxis Oncology will deliver preliminary Phase 1 data in the fourth quarter of 2025 for micvotabart pelidotin, a first-in-concept...

Krystal Biotech reported third-quarter 2025 net product revenue of $97.8 million from Vyjuvek, expanded the U.S. label to include...

Kamada will report third-quarter and nine-month 2025 results before the U.S. market opens on November 10, with an investor...